Compare DXPE & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXPE | OGN |
|---|---|---|
| Founded | 1908 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1998 | 2020 |
| Metric | DXPE | OGN |
|---|---|---|
| Price | $131.40 | $6.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 89.2K | ★ 3.2M |
| Earning Date | 06-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ 27.25 | N/A |
| EPS | ★ 5.37 | 0.72 |
| Revenue | $1,247,043,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $6.88 | $0.42 |
| Revenue Next Year | $7.10 | $1.67 |
| P/E Ratio | $24.26 | ★ $8.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $67.68 | $6.18 |
| 52 Week High | $171.70 | $15.88 |
| Indicator | DXPE | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 30.98 |
| Support Level | $107.83 | $6.18 |
| Resistance Level | $154.19 | $7.87 |
| Average True Range (ATR) | 8.60 | 0.25 |
| MACD | -2.43 | -0.05 |
| Stochastic Oscillator | 5.28 | 7.24 |
DXP Enterprises Inc is engaged in the business of distributing maintenance, repair and operating (MRO) products, equipment and service to customers in various end markets, including general industrial, energy, food & beverage, chemical, transportation, water and wastewater. The company operates through three business segments: Service Centers, Innovative Pumping Solutions and Supply Chain Services. The majority of revenue is derived from the Service Centers segment, which provides a wide range of MRO products in the rotating equipment, bearing, power transmission, hose, fluid power, metal working, fastener, industrial supply, safety products and safety services categories. Geographically, it generates the maximum revenue from the United States.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.